SCHEDULE 13G/A: Allogene Therapeutics Insider David D. Chang Discloses 5.1% Beneficial Ownership Stake
Beneficial Ownership Report
Dr. David D. Chang, a key insider at Allogene Therapeutics, Inc., has filed an amended Schedule 13G disclosing a beneficial ownership of 5.1% of the company's common stock as of December 31, 2024.
Summary
- Dr. David D. Chang, M.D., Ph.D., beneficially owns an aggregate of 10,905,003 shares of Allogene Therapeutics, Inc. common stock, representing 5.1% of the class.
- This ownership includes 5,226,158 shares issuable from stock options and 105,934 shares from Restricted Stock Units (RSUs), both exercisable/releasable within 60 days of December 31, 2024.
- Dr. Chang's beneficial ownership also encompasses shares held by three family trusts for which he serves as co-trustee: 1,201,108 shares from the Chang 2006 Family Trust (0.6% of class), 856,044 shares from the JEC 2019 Trust (0.4% of class), and 856,044 shares from the RTC 2019 Trust (0.4% of class).
- The percentage of class is calculated based on 209,672,091 shares of common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2024.
- Dr. Chang holds sole voting and dispositive power over 7,991,807 shares and shared voting and dispositive power over 2,913,196 shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard regulatory disclosure of significant beneficial ownership by an insider, Dr. David D. Chang, in Allogene Therapeutics, Inc., a biotechnology company. Such disclosures provide transparency to the market regarding the holdings of key individuals, which can be a signal of confidence or lack thereof, though this specific filing is an amendment updating an existing significant stake.
Related Party Transactions
- Dr. David D. Chang's beneficial ownership includes shares held by the Chang 2006 Family Trust, JEC 2019 Trust, and RTC 2019 Trust, for which he serves as co-trustee, indicating a related party relationship in the ownership structure.
Stakeholder Impact
- Shareholders: Provides transparency regarding the significant ownership stake of a key insider, Dr. David D. Chang, and related family trusts, which can influence investor perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date of shares outstanding calculation (209,672,091 shares) as reported in the Issuer's Form 10-Q. |
| 2024-11-07 | Date of filing of the Issuer's Quarterly Report on Form 10-Q, which reported the shares outstanding. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-02-13 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Allogene Therapeutics, David D. Chang, Beneficial Ownership, Schedule 13G, Common Stock, Insider Ownership, Stock Options, Restricted Stock Units, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.